Two teams have shown that Rev-ERBAs play a central role in regulating the circadian clock and metabolism, and a third group has found that agonizing the receptors treated obesity in mice, suggesting Rev-ERBA agonists could help treat a range of metabolic diseases. Next, agonists with longer half-lives will need to be developed and patient populations that might benefit from the molecules will have to be identified.